Annexin A5 - Immunomodulation
Alternative Names: Annexin V - Immunomodulation; IMM 010 - ImmunomodulationLatest Information Update: 28 Jun 2022
At a glance
- Originator Stanford University
- Developer Immunomodulation; Stanford University; University of South Alabama
- Class Antibacterials; Antineoplastics; Antivirals; Proteins
- Mechanism of Action Phosphatidylserine receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Chikungunya virus infections; Dengue; Ebola virus infections; Listeria infections; Marburg virus disease; Zika virus infection
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Breast-cancer in USA
- 28 Jun 2022 No recent reports of development identified for preclinical development in Dengue in USA
- 28 Jun 2022 No recent reports of development identified for preclinical development in Ebola-virus-infections in USA